Tirzepatide effectively provides good glycaemic control in diabetes patients undergoing hemodialysis: Study

Tirzepatide is an injectable peptide approved by the US Food and Drug Administration for the treatment of Type 2 diabetes (T2DM). Its weight-loss effect primarily targets fat reduction; however, such effect on patients with chronic kidney disease (CKD) undergoing haemodialysis (HD) has not been reported. Nine patients with chronic kidney disease undergoing haemodialysis received weekly tirzepatide doses (2.5-7.5 mg) once a week. Evaluations encompassed tirzepatide’s impact on dry weight (DW) and body composition assessed at baseline and study conclusion using bioelectrical impedance analysis. This longitudinal study included nine patients, with a median age of 53 years and median haemodialysis duration of 4 years. RESULTS: Tirzepatide treatment significantly decreased glycated albumin compared with the value at baseline (22.7 ± 5.4 vs. 18.3 ± 2.5%, p = 0.028, respectively). Significant reductions were observed in DW (-1.0 kg, p = 0.024) and body mass index (-0.6 kg/m2, p = 0.050) following tirzepatide administration. Total fat mass was also reduced, but not significantly (- 2.51% from baseline, p = 0.214). In contrast, skeletal muscle mass was not decreased (-1.02% from baseline, p = 0.722). No serious side effects other than nausea were observed during the study period. Tirzepatide effectively provides good glycaemic control in Type 2 diabetes patients undergoing haemodialysis, decreasing dry weight by reducing body fat mass without increasing frailty risk.

Keywords:

Tirzepatide, effectively, provides, good, glycaemic, control, diabetes, patients, undergoing, hemodialysis, study, Mima, Akira, and Yasuhiro Horii